Medications
Drugs that act on granulopoiesis: G-CSF, GM-CSF, chemotherapy effects on the marrow, leukemia therapies that target the myelocyte stage.
Randomized trial of recombinant G-CSF, the drug that acts directly on the granulocytic precursor pool.
Review of agents that push arrested leukemic precursors toward mature forms.
Review of therapeutic angles on myeloid immunosuppression, including immature neutrophil populations.
Blocking CysLTR1 reprograms tumor-promoting myelopoiesis and restores checkpoint therapy response. Preclinical.
Single case of agranulocytosis attributed to semaglutide, treated with G-CSF.
Macrocyclic peptides inhibit NSP4, a serine protease stored in primary (azurophilic) granules of myeloid precursors; potent and selective, with crystal structures solved.
IP G-CSF drives human-like myeloid expansion in NSG humanised mice without systemic inflammation; supports the G-CSF context state: accelerated transit and pool expansion without a cytokine storm.
Synthetic sulfonamide intermediate promotes neutrophil maturation and reduces mortality in a sepsis model; the mechanism runs through the myeloid differentiation program.
Triterpenes from Euphorbia systyloides tested for antiparasitic activity; appeared in scan via neutrophil cytotoxicity assay used as a counter-screen. Tangential to myelocyte biology.
Spirocyclic alkaloids from a mangrove endophytic fungus tested for cytotoxicity including against myeloid cell lines; appeared via neutrophil assay counter-screen. Tangential to myelocyte biology.